JB Chemicals & Pharmaceuticals Limited — Updates, 30-07-2025: Press Release

JB Pharma delivered robust Q1 FY26 performance: Revenue rose 9% to ₹1,094 Cr, Operating EBITDA jumped 13% to ₹330 Cr, and Net Profit increased 14% to ₹202 Cr. Domestic formulations, fastest growing among top 25 pharma, drove growth up 14% to ₹678 Cr across acute, chronic, and ophthalmology segments. Operating EBITDA margins reached a record 30.2%, signaling strong profitability. CDMO business also grew 8%, with positive momentum expected.